FABP3 and glioma: In lower grade gliomas (grade II–III), moderate to high MDGI levels significantly associated both with poor glioma‐specific (HR = 1.85; 95% CI: 1.08–3.16; P = 0.022; Appendix Fig S1A) and poor overall survival of patients (HR = 1.98; 95% CI: 1.19–3.28; P = 0.007; Fig 1B) as compared to patients with negative or low tumour MDGI expression.